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Background Basilar-type Migraine (BM) and Familial Hemiplegic
Migraine (FHM) are phenotypically similar subtypes of migraine with
aura, differentiated only by motor symptoms, which characterize FHM.
The latter is thus far the only migraine subtype in which mutations
have been found in the CACNA1A and ATP1A2 genes.
Methods We looked for mutations in CACNA1A and ATP1A2 in mem-
bers of a family with BM. Screening was performed by direct sequenc-
ing on blood genomic DNA.
Results No mutations were found in CACNA1A. However, we iden-
tified a novel point mutation in exon 12 of the ATP1A2 gene result-
ing in replacement of arginine 548 with histidine (R548H). Four indi-
viduals of this family carried the mutation, which was absent in 400
control chromosomes and in 174 chromosomes from unrelated
migraineurs. “A posteriori” genotyping was consistent with linkage
to the FHM2 locus.
Conclusions In this study we report a novel mutation in the ATP1A2
gene (R548H) in a family with Basilar-type Migraine, a subtype of
migraine with aura phenotypically close to FHM. This is the first report
of an ATP1A2 gene mutation in a form of migraine other than FHM.
This finding suggests that BM and FHM may be allelic disorders.
THE BLINK REFLEX IN CHRONIC MIGRAINE
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Objectives Activation of the trigeminovascular system as well as of
brainstem trigeminal nuclei are thought to play an important role in
migraine. The aim of this study was to investigate the habituation phe-
nomenon of the blink reflex in “chronic migraine”.
Patients and methods An EMG device with a specific habituation test
program was used to elicit and record blink reflex responses on both
the right and left sides, and to randomly repeat the stimulations at dif-
ferent time intervals in order to induce habituation. We studied 15
patients suffering from “chronic migraine” (diagnosed according to the
IHS classification criteria) and 15 control subjects.
Results Whereas the R1 and R2 latencies, amplitudes and areas in
the basal assessment were similar in patients and control subjects,
the blink reflex habituation responses were markedly reduced in
patients with “chronic migraine”. In these patients, the differences
between the R2 areas, obtained when stimuli were delivered at sub-
sequent time intervals ranging between 10–5, 5–4, 4–3 and 3–2 sec-
onds, were statistically different (p<0.001) from those of controls
subjects.
Conclusions Our data suggest that the brainstem pathways involved in
the blink reflex may be activated in chronic migraine, probably through
mechanisms that involve dopaminergic function. 
CUTANEOUS ALLODYNIA AND CEREBROSPINAL FLUID
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Introduction Cutaneous allodynia has been described during migraine
attack. Repeated measurements of mechanical and thermal pain thresh-
olds of periorbital and forearm skin areas verified the occurrence of
cutaneous allodynia during migraine in 79% of migraine patients.
Cutaneous allodynia occurred either solely within the referred pain area
on the ipsilateral head, or within and outside the ipsilateral head [1, 2].
Allodynia is considered a manifestation of central sensitization, but it is
not routinely evaluated during clinical interviews even though its ther-
apeutic implications are known [3]. In particular, no studies have been
performed on cutaneous allodynia in patients with chronic migraine
(CM) and its biochemical correlates have never been investigated.
Patients Fifty consecutive CM patients diagnosed according to ICHD-
II Classification were included in the study and evaluated using a semi-
structured questionnaire. Thirty CM patients underwent lumbar punc-
ture, and measurements of glutamate were performed using HPLC.
Results Forty-eight (96%) CM patients reported allodynia. Twenty-
seven (54%) had cephalic, 18 (36%) had both cephalic and extra-
cephalic, and 3 (6%) exhibited pure extracephalic allodynia. Scalp
allodynia was ipsilateral to the predominant headache side in the
majority of patients and occurred at the height of the headache.
Extracephalic allodynia of the upper extremities occurred in 8 (16%),
and of the toes in 2 (4%). Truncal allodynia occurred in 3 (6%).
Correlation was found between the duration of headache, and in par-
ticular, chronic headache and allodynia. The subgroup of patients with
cutaneous allodynia exhibited higher CSF glutamate levels than
healthy control subjects, all without evidence of cutaneous allodynia
(p<0.01). CSF glutamate levels were greater in patients with both
cephalic and extracephalic allodynia than in those with only cephalic
or extracephalic allodynia.
Conclusions The present study supports the occurrence of detectable
allodynia in the majority of CM patients. This is associated with high-
er glutamate levels, which can be considered the biochemical counter-
part of central sensitization of second-order and third-order neurons in
chronic migraine patients.
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MODULATION VIA NOP1 RECEPTOR OF CGRP AND NITRIC
OXIDE RELEASE IN AN IN VITRO MODEL OF TRIGEMINAL
NEURON ACTIVATION
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Background Nitric oxide (NO) and calcitonin gene-related peptide
(CGRP) are important mediators of vasodilation of blood vessels and
are also algogenic substances. Both mediators are released from
trigeminal ganglion neurons; recently NO was indicated as one of the
molecules most involved in sensitization and thus in chronic headache.
Nociceptin is a relatively novel peptide, which interacts with the NOP1
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(ORL1) receptor, but does not bind classical opiod receptors; noci-
ceptin produces in vivo supraspinal analgesic effects and is involved in
antagonism of allodynia and hyperalgesia of noxious stimuli. The aim
of our study was to investigate which mechanisms are involved in
release of NO and CGRP, using the model of trigeminal ganglion neu-
rons in culture, and how nociceptin could modulate this secretion.
Methods Trigeminal ganglion neurons in culture were prepared as
described in previous studies. Briefly, ganglia from 6–7-day-old rats
were quickly removed and digested by collagenase and trypsin, and
finally neurons were collected through Percoll spin centrifugation. For
plating we used from 120 to 150x103 cells per dish. IL-1β was used as
proinflammatory stimulus. Immunocytochemical analysis against neu-
rofilament 200 was performed to demonstrate purified neurons in cul-
ture. First, we evaluated the trend in IL-1β-induced release of CGRP
and NO from cultures of trigeminal neurons and which concentration
of IL-1 was more effective. Afterward, we evaluated CGRP and NO
release by stimulation of the NOP1 receptor with a potent agonist, such
as nociceptin-NH2, in two experimental conditions: (1) trigeminal neu-
rons pre-treated with IL-1β, and (2) without pre-treatment.
Results At 24–48 hours, IL-1β induced maximal release of CGRP
and NO; these findings confirm the data in the literature for CGRP
and show a similar release pattern for NO. Nociceptin shows differ-
ent modulation of NO and CGRP release in the two experimental
conditions.
Conclusions Nociceptin modulates the secretion of inflammatory
mediators in an in vitro model of trigeminal neuron activation.
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Atrial septal defect and patent foramen ovale (PFO) are present in
approximately 25% of patients at autopsy and 45% of patients with
cryptogenic stroke. Recent reports suggest an increased prevalence of
PFO in migraine with aura (MA) patients and show that PFO closure
reduces attack frequency. Transcranial doppler (TCD) is a very sensi-
tive tool for detecting microembolic signals in the cerebral circulation
after injection of saline solution mixed with air in cases of right-to-left
shunt. Most of the studies in the literature are retrospective assessments
and evaluate the modification of attack frequency after PFO closure in
MA patients and migraine patients without (MO) aura. We set out to
evaluate whether PFO is more prevalent among patients with atypical
aura features, consisting of prolonged aura and/or interictal aura. MA
patients who referred to a headache unit in the last year underwent con-
trast-enhanced TCD. The diagnosis of MA was made in accordance
with the revised International Headache Society criteria (ICHD-II).
Each patient underwent a structured interview in which we investigat-
ed family history, cardiocerebrovascular risk factors, comorbidity, and
in detail, the clinical features of aura and headache. All the patients also
underwent thrombophilic screening (antithrombin III, anticoagulant
protein C, functional protein S, resistance to activated protein C, homo-
cysteine, lupus anticoagulant and fibrinogen). We studied 65 subjects
(48 females, mean age 35.2±11.7 years; 17 males, mean age 37±7.7
years). Forty-one (63.1%) of these patients fulfilled the criteria for typ-
ical aura and 24 (39.9%) for atypical aura. PFO was more prevalent in
the subjects with atypical aura features than in those presenting typical
aura (79.17% vs. 46.3%; OR 4.4; CI 1.4–14.0). When we compared the
two aura groups (typical and atypical), no significant differences
emerged in the thrombophilic markers. Similarly, no significant differ-
ences were found in these markers between the atypical aura subjects
with patent foramen ovale versus atypical aura subjects without patent
foramen ovale, and versus all typical aura patients. Our preliminary
results strengthen the possibility that PFO is most frequently associat-
ed with atypical aura features, but the underlying pathophysiology of
this association is not clear.
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Introduction Cluster Headache (CH) is commonly considered a disor-
der of young men. We report 18 patients with CH over 65 years of age.
Patients and methods We analysed the clinical charts of 7336 con-
secutive patients referred to our Headache Centre from 1995 to 2004.
The elderly patients diagnosed with CH underwent re-evaluation and
follow-up visits.
Results We identified 140 patients with CH, 18 of whom were over age
65. This group of geriatric CH patients consisted of 11 females and 7
males. Most of the patients suffered from episodic CH (12 cases, 7
females and 5 males), while the remaining six cases (4 females and 2
males) were affected by chronic CH. The age at onset occurred in the
decade 35–44 for three males, in the decade 45–54 for one female, in
the decade 55–64 for four females and one male, in the decade 65–74
for four females and one male, and in the decade 75–84 for two
females and two males. Only the three cases with an early age at onset
had several cluster periods, occurring every 1 to 2 years, but less fre-
quently after age 60. The patients with an older age at onset had spo-
radic active periods. In four patients only two bouts occurred, with
remissions ranging from 5 to 28 years, while four other patients had
only one cluster period until now. The characteristics of the pain and
its manner of occurrence were similar to those reported in the younger
population, only the autonomic features seemed to be less prominent.
Discussion Our cases demonstrate that CH, although commonly con-
sidered a young male disorder, may also begin in geriatric age.
Moreover, with regard to onset of CH, we found a significantly higher
number of female patients above age 55. To our knowledge, we report
the most numerous population of elderly patients with CH and the
patient with the oldest age of onset of cluster headache (an 84-year-old
woman) published in the literature to date.
Conclusions The onset of CH seems to be independent of the patients’
period of life, even if the average age of onset peaks towards the third
decade. Apparently peculiar to the female distribution, an increased
frequency appears to occur in middle-aged and elderly patients. In the
geriatric CH group, females represented the majority of cases, in con-
trast with the evident male preponderance in the previous decades.
LONGITUDINAL UPDATE ON QUALITY OF LIFE, BODILY
PAIN, ANXIETY AND DEPRESSION IN PRIMARY
HEADACHE
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In this preliminary study, the time course of quality of life (QoL), bod-
ily pain, anxiety, and depression were documented in sixteen headache
outpatients (3 men and 13 women, mean age 29.31 years, range 21–62)
at the baseline visit, and at 3- and 6-month follow-up visits. During the
study, patients received only symptomatic treatment (simple or combi-
nation analgesics and triptans). No psychological therapies were intro-
duced. QoL was assessed using the medical outcomes study Short Form
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Health Survey (SF-36), a generic, self-administered instrument, which
has been widely used in several chronic disorders [1]. The McGill-
Melzack Pain Assessment Questionnaire was used to assess the quality
and intensity of bodily pain [2]. The Beck Depression Inventory (BDI)
was applied for assessment of depression [3]. Finally, the State-Trait
Anxiety Inventory, form Y [4] was used to assess anxiety traits. In 7 of
16 patients (43.75%), QoL was globally restored to the baseline visit
level three months after recruitment. Nearly identical prevalences were
observed at the 3-month and 6-month follow-up visits. The patients’
perception of bodily pain showed only marginal changes or remained
stable at the two follow-up visits. Depression was a common finding at
the baseline visit (75% had a BDI score indicating mild to moderate or
moderate to severe depression). At the six-month follow-up, in 6 of 16
patients (37.5%) a degree in reduction of the depressive disorder was
observed. The percentage of patients with anxiety traits (81.2%) also
showed a declining trend in 12 of 16 patients (75%). The results of this
preliminary report highlight the importance of health status evaluation
as an essential step in the longitudinal assessment of patients with
headache attending a headache centre.
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Background From birth, human beings have individual emotional and
behavioural characteristics, in particular, they have different reactivity.
This is a characteristic strongly linked to the concept of temperament
[1], and some authors considered it as an early temperamental trait [2].
Some infants (15%) presented a number of behavioural and physical
peculiarities, in particular, they showed a low threshold of sensory
stimulation and a lack of habituation to stimuli: the hyperactive (HPR)
neonates [3]. Recent studies suggested that a low threshold of neuro-
physiological reactions and a lack of habituation are the principal
abnormalities of sensory processing in migraineurs [4].
Objective To evaluate, after at least 15 years, the prevalence of prima-
ry headache in HPR infants.
Subjects and methods In 2003, we contacted 100 children (60 M, 40
F, mean age=17.5 years): 50 with at least 2 symptoms of HPR, 50 with-
out; the groups were similar for age and gender. All infants were visit-
ed between 1 and 18 months of life at the Puericulture Institute of “La
Sapienza”. We administered a revised headache questionnaire [5],
using chi-square test.
Results Twenty-one (43.2%) HPR infants suffered from migraine
(69% were coded 1.6.1) vs. 5 (10.3%) of the control group (25% were
1.6.1) (p<0.05); 19 (37.8%) suffered from TTH (57% were 2.4.1) vs.
15 (30.7%) of the control group (83% were 2.4.1).
Discussion The HPR neonates showed an “amplified” response to
environmental stimuli [3] that was correlated with a real variation of
brain electrical activity, i.e., an increased amplitude of evoked poten-
tials [6]. Both evoked potential and transcranial magnetic stimulation
studies showed that the cerebral cortex, and possibly subcortical struc-
tures, are dysfunctioning in migraine. These electrophysiologic abnor-
malities, whose hallmark is deficient habituation, tend to normalise just
before and during an attack [4]. From these electrophysiologic data and
from the greater incidence of migraine in our experimental group, we
can hypothesize that neonatal hyperactivity represents the first step in
CNS hypersensitivity which, during childhood, could manifest itself as
migraine. It is also true that a reduced ability to ignore novel or repeat-
ed stimuli influences behaviour and cognition [7], and that certain per-
sonality traits are assumed to predispose to the development of partic-
ular diseases [8]. This is important for prevention, treatment and recov-
ery from the disease. 
Conclusions HPR, a part of negative emotionality, already proved to be
related to psychosomatic disorders [9] of temperament, is an important
risk factor for developing migraine, but not other primary headaches.
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